Compare CRNX & OII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | OII |
|---|---|---|
| Founded | 2008 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 1994 |
| Metric | CRNX | OII |
|---|---|---|
| Price | $83.73 | $52.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $76.75 | $31.33 |
| AVG Volume (30 Days) | ★ 6.8M | 1.2M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.36 |
| EPS | N/A | ★ 1.00 |
| Revenue | $1,039,000.00 | ★ $2,784,156,000.00 |
| Revenue This Year | $720.10 | $2.83 |
| Revenue Next Year | $184.67 | $5.34 |
| P/E Ratio | ★ N/A | $133.39 |
| Revenue Growth | N/A | ★ 4.62 |
| 52 Week Low | $25.83 | $20.79 |
| 52 Week High | $84.00 | $51.48 |
| Indicator | CRNX | OII |
|---|---|---|
| Relative Strength Index (RSI) | 92.07 | 82.37 |
| Support Level | $33.50 | $34.66 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.18 | 1.89 |
| MACD | -0.10 | 0.85 |
| Stochastic Oscillator | 53.51 | 98.57 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.